IJCS | Volume 31, Nº3, Maio / Junho 2018

306 1. Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb Al. Cystatin C as a marker of GFR – history, indications, and future research. Clin Biochem. 2005 Jan;38(1):1-8. doi: 10.1016/j. clinbiochem.2004.09.025. 2. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? ClinChem. 2002;48(5):699-707. PMID: 11978596. 3. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221-6. doi: 10.1053/ajkd.2002.34487. 4. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36(1):29-34. doi: 10.1053/ajkd.2000.8237. 5. Windhausen F, Hirsch A, Fischer J, van der Zee PM, Sanders GT, van Straalen JP, et al; Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem. 2009;55(6):1118-25. doi: 10.1373/clinchem.2008.119669. 6. Taglieri N, Fernandez-Berges DJ, Koenig W, Consuegra-Sanchez L, Fernandez JM, Robles NR, et al; SIESTA Investigators. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis. 2010;209(1):300-5. doi: 10.1016/j.atherosclerosis.2009.09.022. 7. Ichimoto E, Jo K, Kobayashi Y, Inoue T, Nakamura Y, Kuroda N, et al. Prognostic significance of cystatin C in patients with ST-Elevation myocardial infarction. Circ J. 2009;73(9):1669-73. doi: https://doi. org/10.1253 /circj.CJ- 08-0943 8. Ferraro S, Marano G, Biganzoli EM, Boracchi P, Bongo AS. Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target. Clin Chem Lab Med. 2011;49(9):1397-404. doi: 10.1515/CCLM.2011.607. 9. BiM, Huang Z, Li P, ChengC, Huang Y, ChenW. The association between elevated cystatin C levels with myocardial infarction: a meta-analysis. Int J Clin Exp Med. 2015;8(11):20540-7. PMID: 26884971. 10. Lee M, Saver JL, Huang WH, Chow J, Chang KH, Ovbiagele B. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes. 2010;3(6):675-83. doi: 10.1161/ CIRCOUTCOMES.110.957696. 11. Li R, Hao P, Chen Y, Zhang Y. Association of cystatin C level and cardiovascular prognosis for patients with preexisting coronary heart disease: a meta-analysis. Chin Sci Bull. 2014;59(5-6):539-45. 12. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group preferred reporting items for systematic reviews and meta- analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal. pmed.1000097. 13. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–OttawaScale(NOS)forassessingthequalityofnonrandomized studies in meta-analysis [Internet]. Ottawa Hospital Research Institute. Canada: University of Ottawa, Department of Epidemiology and Commuunity Medicine. 2017 [Access in 2017 21 Feb]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 14. Nicolau JC, Timerman A, Marin-Neto JA, Piegas LS, Barbosa CJ, Franci A, et al; Sociedade Brasileira de Cardiologia. [Guidelines of Sociedade Brasileira de Cardiologia for unstable angina and non-ST-segment elevationmyocardial infarction (II edition, 2007) 2013-2014 update]. Arq Bras Cardiol. 2014;102(3 Suppl 1):1-61. doi: http://dx.doi.org/10.5935/ abc.2014S001. 15. Tonkin AM, Blankenberg S, Kirby A, Zeller T, Colquhoun DM, Funke- Kaiser A, et al; LIPID study investigators. Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. Int J Cardiol. 2015 Dec 15;201:499-507. doi: 10.1016/j. ijcard.2015.07.080. 16. Akerblom Å, Wallentin L, Siegbahn A, Becker RC, Budaj A, Buck K, et al. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. Clin Chem. 2012;58(1):190-9. doi: 10.1373/ clinchem.2011.171520. 17. Tang L, Fang ZF, Zhou SH, Tai S, Ahmed S, Huang F, et al. Association of serum Cystatin C levels with myocardial perfusion and cardiac functional recovery in patients with anterior wall ST elevationmyocardial infarction treated with primary coronary intervention. Heart Vessels. 2015.31(9):1456-66. doi: 10.1007/s00380-015-0764-z. 18. Fu Z, Xue H, Guo J, Chen L, Dong W, Gai L, et al. Long-term prognostic impact of Cystatin C on acute coronary syndrome octogenarians with diabetes mellitus. Cardiovasc Diabetol. 2013 Nov 1;12:157. doi: 10.1186/1475-2840-12-157. 19. Akgul O, Uyarel H, Ergelen M, Pusuroglu H, Gul M, Turen S, et al. Predictive value of elevated cystatin C in patients undergoing primary angioplasty for ST-elevation myocardial infarction. J Crit Care. 2013;28(5):882.e13-20. doi: 10.1016/j.jcrc.2013.03.004. 20. WideraC, PencinaMJ, BobadillaM, Reimann I, Guba-Quint A,Marquardt I, et al. Incremental prognostic value of biomarkers beyond the GRACE (Global Registry of Acute Coronary Events) score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome. Clin Chem. 2013;59(10):1497-505. doi: 10.1373/clinchem.2013.206185. 21. Manzano-Fernández S, López-Cuenca Á, Januzzi JL, Parra-Pallares S, Mateo-Martínez A, Sánchez-Martínez M, et al. Usefulness of ß-trace protein and cystatin c for the prediction of mortality in non ST-segment elevation acute coronary syndromes. Am J Cardiol. 2012;110(9):1240-8. doi: 10.1016/j.amjcard.2012.06.027. 22. Ristiniemi N, Lund J, Tertti R, Christensson A, Ilva T, Porela P, et al. Cystatin C as a predictor of all-cause mortality andmyocardial infarction in patients with non-ST-elevation acute coronary syndrome. Clin Biochem. 2012;45(7-8):535-40. doi: 10.1016/j.clinbiochem.2012.02.012. 23. Silva D, Cortez-Dias N, Jorge C, Marques JS, Carrilho-Ferreira P, Magalhães A, et al. Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction. Am J Cardiol. 2012;109(10):1431-8. doi: 10.1016/j.amjcard.2012.01.356. 24. Sun TW, XuQY, YaoHM, Zhang XJ, WuQ, Zhang JY, et al. The predictive value of plasma Cystatin C for acute coronary syndrome treated with percutaneous coronary intervention. Heart Lung. 2012;41(5):456-62. doi: 10.1016/j.hrtlng.2012.04.007. 25. Kaski JC, Fernández-Bergés DJ, Consuegra-Sánchez L, Fernández JM, García-Moll X, Mostaza JM, et al. A comparative study of biomarkers for risk prediction in acute coronary syndrome—results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. Atherosclerosis. 2010;212(2):636-43. doi: 10.1016/j. atherosclerosis.2010.06.026. Referências Martucheli et al. Cistatina C e síndromes coronarianas agudas International Journal of Cardiovascular Sciences. 2018;31(3)290-307 Artigo de Revisão Vinculação Acadêmica Não há vinculação deste estudo a programas de pós- graduação. Aprovação Ética e consentimento informado Este artigo não contém estudos com humanos ou animais realizados por nenhum dos autores.